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Abstract
Background: Most ovarian cancers are highly invasive in nature and the high burden of metastatic disease
make them a leading cause of mortality among all gynaecological malignancies. The homeodomain
transcription factor, PITX2 is associated with cancer in different tissues. Our previous studies demonstrated
increased PITX2 expression in human ovarian tumours. Growing evidence linking activation of TGF-β pathway
by homeodomain proteins prompted us to look for the possible involvement of this signalling pathway in
PITX2-mediated progression of ovarian cancer.
Methods: The status of TGF-β signalling in human ovarian tissues was assessed by immunohistochemistry. The
expression level of TGFB/INHBA and other invasion-associated genes was measured by quantitative-PCR (Q-PCR)
and Western Blot after transfection/treatments with clones/reagents in normal/cancer cells. The physiological
effect of PITX2 on invasion/motility was checked by matrigel invasion and wound healing assay. The PITX2- and
activin-induced epithelial-mesenchymal transition (EMT) was evaluated by Q-PCR of respective markers and
confocal/phase-contrast imaging of cells.
Results: Human ovarian tumours showed enhanced TGF-β signalling. Our study uncovers the PITX2-induced
expression of TGFB1/2/3 as well as INHBA genes (p < 0.01) followed by SMAD2/3-dependent TGF-β signalling
pathway. PITX2-induced TGF-β pathway regulated the expression of invasion-associated genes, SNAI1, CDH1
and MMP9 (p < 0.01) that accounted for enhanced motility/invasion of ovarian cancers. Snail and MMP9 acted
as important mediators of PITX2-induced invasiveness of ovarian cancer cells. PITX2 over-expression resulted in
loss of epithelial markers (p < 0.01) and gain of mesenchymal markers (p < 0.01) that contributed significantly to
ovarian oncogenesis. PITX2-induced INHBA expression (p < 0.01) contributed to EMT in both normal and ovarian
cancer cells.
Conclusions: Overall, our findings suggest a significant contributory role of PITX2 in promoting invasive
behaviour of ovarian cancer cells through up-regulation of TGFB/INHBA. We have also identified the previously
unknown involvement of activin-A in promoting EMT. Our work provides novel mechanistic insights into the
invasive behavior of ovarian cancer cells. The extension of this study have the potential for therapeutic
applications in future.
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Background
Ovarian cancer is a highly metastatic disease and is the
leading cause of death among all gynaecological malignan-
cies [1]. Unfortunately, the disease is often detected at an
advanced stage (stages III-IV) and progresses very rapidly,
as it acquires an aggressive phenotype. A number of growth
factors, including transforming growth factor-β (TGF-β)
regulate the proliferation of ovarian surface epithelial (OSE)
cells and increases metastasis [2]. TGF-β binds to its spe-
cific receptors, type-I (TβRI) and type-II (TβRII). Upon lig-
and binding, TβRII trans-phosphorylates and activates
TβRI, which in turn phosphorylates Smad2 and Smad3
[3, 4]. The latter two then bind to Smad4 and the com-
plex translocates to the nucleus to regulate the expres-
sion of target genes. Other member of the TGF-β
superfamily, like activin transduces signals mainly
through the SMAD2/3-dependent pathway [5]. INHBA
forms a disulfide-linked homodimer, known as activin-
A which is a polypeptide hormone of primarily gonadal
origin [6, 7]. The mojor gonadal sites of its production
is Sertoli cells of males and ovarian granulosa cells of
female origin [6, 7]. High levels of activin-βA subunit is
detected in majority of the patients with granulosa cell
tumors [8], but almost absent in ovarian epithelial tumors
except mucinous carcinoma [9]. In addition, increased ex-
pression of activin-A is observed in esophageal [10] and
colorectal carcinomas [11]. High expression of activin-A
was found in stage IV colorectal cancer [12] and correlated
with poor overall survival rate [11, 12]. However, there are
no reports on the regulation of activin-A and its role in
epithelial ovarian cancer progression.
Highly invasive and metastatic behavior underpin the ag-
gressive nature of ovarian cancers. Epithelial-mesenchymal
transition (EMT) is a major mechanism for the conversion
of early-stage tumors to invasive malignancies due to the
loss of epithelial adherence and tight junctions [13, 14].
Transcription factor like Snail acts as a key regulator in the
induction of cellular invasion, in part, by suppressing the
expression of the epithelial specific adhesion molecule, E-
cadherin and by increasing the expression of matrix metal-
loproteinases MMPs; [15]. TGF-β-signalling, on the other
hand, enhances the invasive properties of ovarian cancers
partially through up-regulation of MMPs [16].
The homeobox genes are widely implicated in various
human cancers, acting as oncogenes or tumour suppres-
sors [17–21]. Pituitary homeobox 2 (PITX2), a member
of the bicoid/paired-like homeobox gene family, is a
multifunctional transcription factor [22–24]. Three dif-
ferent isoforms of PITX2 (PITX2A/B/C), differ only in
their amino terminus and regulate the transcription of
target genes differentially [25]. Recently, several reports
highlighted the association of PITX2 with progression of
breast and colorectal cancers [26, 27]. We observed the
up-regulated expression of PITX2 in ovarian tumours
[28] and simultaneously we found induced TGF-β sig-
naling pathway in the same tissue sections. Consider-
ing the importance of TGF-β signalling pathway in
promoting oncogenesis of several tissues, we aimed to
investigate possible involvement of PITX2 in promot-
ing invasiveness of ovarian cancer cells through the
regulation of TGF-β signalling pathways. We also ex-
plored the role of activin-A in the progression of epi-
thelial ovarian cancers.
Results
Activation of TGF-β signalling pathway in human ovarian
tumours
We evaluated the status of TGF-β signalling in ovarian
tumours. The level of phospho-SMAD2, (as readout of ac-
tive TGF signalling; Fig. 1a) was measured by immunohis-
tochemical analysis. Confocal imaging of tissue sections
showed intense staining of p-SMAD2 in human ovarian
cancer (ii) compared to normal (i) tissues, supporting the
activation of TGF-β signalling pathway. The specificity of
the staining was checked by staining the sections in pres-
ence of secondary antibody only and DAPI without primary
antibody (Fig. 1b). Simultaneously, the increased expression
of PITX2 was observed in the same ovarian tumor sections
(i) compared to normal (ii) (Additional file 1: Figure S1).
SMAD-dependent TGF-β signalling is activated by PITX2
in ovarian cancer cells
Considering the association of homeodomain proteins in
activating TGF-β signalling in different cancer types, we
attempted to investigate whether PITX2 could activate
the same in ovarian cancer cells. For that, the increased
expression of PITX2 was verified by Western blot with
lysate of PITX2A-transfected OAW-42 cells (Fig. 2a).
The ectopic over-expression of PITX2A/B/C signifi-
cantly enhanced the mRNA levels of TGF-B1/B2/B3 in
OAW-42 (p < 0.01; Fig. 2b) cells as shown by Q-PCR
assay. Similarly, increase in TGF-B2/B3 was observed
in SKOV-3 (p < 0.01; Fig. 2c) cells upon over-expression of
PITX2 isoforms. The incubation of freshly cultured cells
with the conditioned medium of PITX2A-transfected cells
(PITX2-CM) induced the p-SMAD2 level. This induction
was reduced in presence of TGF-β receptor inhibitor
(TGFRI), suggesting the involvement of PITX2-mediated
activation of TGF-β signalling pathway both in SKOV-3
(Fig. 2d) and OAW-42 cells (Fig. 2e). Here, the treatment
of cells with rhTGFβ-1 also activated the p-SMAD2 level as
a mark of positive control (Fig. 2d-e). The nuclear p-
SMAD2 level was enhanced by the treatment of
SKOV-3 cells with PITX2-CM as observed by confocal
imaging using specific antibody (Fig. 2f ). In contrast,
treatment with rhTGFβ1 in PITX2-siRNA transfected
cells reduced the intensity of expression. Here, the re-
duction in PITX2 protein was confirmed by Western
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blot with PITX2-siRNA trasfected cell lysate (Fig. 2g).
Further, the ectopic over-expression of PITX2A/B/C aug-
mented the activity of TGFβ/SMAD-responsive reporter
construct (p3TP-lux) by 3-5 folds (Fig. 2h) in OAW-42
cells, however, TGFRI-treatment suppressed this trans-
activation (Fig. 2h). Taken together, the results suggest acti-
vation of TGF-β signalling pathway by PITX2.
PITX2 contributes to the EMT and invasion of ovarian
cancer cells
In conjunction with our earlier finding of the up-
regulated expression of PITX2 in human ovarian tumors
[20], we attempted to check the regulation of invasion-
associated genes by PITX2. The transient transfection of
PITX2 isoforms significantly increased the expression of
these genes like Snail (SNAI1), Slug (SNAI2) and MMP9
in both SKOV-3 (Fig. 3a) and OAW-42 cells (Fig. 3b). In
contrast, PITX2 over-expression reduced the mRNA
level of E-cadherin (Fig. 3a-ii) in OAW-42 cells. Since
EMT is an essential prerequisite for the metastasis of
ovarian cancer, we tried to elucidate the role of PITX2
over-expression in inducing EMT. PITX2 isoforms sig-
nificantly reduced (p < 0.01; Fig. 2c-i) the expression of
epithelial marker genes claudin-4 (CLD4), claudin-7
(CLD7) and desmoplakin (DSM), whereas the mesenchy-
mal gene, vimentin (VIM; Fig. 3c-ii) was induced by all
isoforms of PITX2 in SKOV-3 cells. Similarly, the ex-
pression of CLD4, CLD7 and DSM (Fig. 3d-i; p < 0.05)
were reduced while that of VIM (Fig. 3d-ii; p < 0.005)
was up-regulated in PITX2-overexpressed OAW-42
cells. Consistently, the expression of α-smooth muscle
actin (α-SMA, a mesenchymal marker) was more intense
in PITX2-transfected SKOV-3 (Fig. 3e) and OAW-42
(Fig. 3f ) cells as shown by Western-immunobloting.
However, the protein level of claudin-7 was remarkably
reduced in PITX2 over-expressed SKOV-3 (Fig. 3e) and
OAW-42 (Fig. 3f ) cells. The EMT-like phenotypical
changes in IOSE cells were verified by bright field mi-
croscopy (Fig. 3g-i) and the actin rearrangement was
observed by phalloidin staining (Fig. 3h-i). SKOV-3
cells also showed phenotypic changes upon PITX2A-
overexpression in phase contrast microscopy (Fig. 3g-ii). A
significant decrease in E-cadherin was observed by immu-
nostaining in PITX2A-transfected cells compared to con-
trols (Fig. 3h-ii). There was a significant decrease (p < 0.01;
Fig. 3i) of the epithelial markers CLDN1 and CLDN7, while
Fig. 1 The expression of p-SMAD2 is up-regulated in human ovarian cancer. a The level of p-SMAD2 was shown by IHC in human ovarian
tissue-sections with p-SMAD2 antibody followed by Alexa Fluor-488 (green) of normal (i; n = 20) and ovarian tumor (ii; n = 20), out of which
15 samples are of high grade and 5 samples are benign. The DAPI-stained nuclei and the merged images were also shown. b The negative
control images represent the staining in presence of secondary antibody and DAPI but without primary antibody. The images were taken at
the same exposure time. Scale bar, 10 μm
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mesenchymal markers like N-cadherin (CDH2) and VIM
showed ~ 4.5-5.5 fold up-regulation (Fig. 3j) in IOSE cells
transfected with PITX2A. Similar changes in parameters
primarily observed during EMT were also noticed in PITX2
over-expressed cells.
Migration and invasion of ovarian cancer cells are
enhanced by PITX2 through TGF-β pathway
To address the physiological significance of PITX2-
mediated regulation of TGF-β pathway in promoting
migration and invasion, wound healing assay was per-
formed with SKOV-3 (Fig. 4a) and OAW-42 (Fig. 4b)
cells. Treatment with rhTGF-β1 (ii) for 24 h or transient
transfection of PITX2A (iii) for the same duration exhib-
ited faster wound closure than the control set (i). Treat-
ment of transiently transfected cells with rhTGF-β1 (iv)
showed almost complete healing within the same period.
Conversely, TGFRI-treatment (v) inhibited the healing,
while ectopic over-expression of PITX2A slightly re-
duced its inhibitory effect (vi). The gap created by the
wound before and after treatment/transfection has been
depicted herewith. Matrigel invasion assay demon-
strated ~2.5 folds increase (p < 0.005; Fig. 4c and e) in in-
vasion of SKOV-3 cells upon transient transfection of
Fig. 2 PITX2 induces TGF-β signalling pathway in ovarian cancer cells. a Western blot was performed with the lysate of OAW-42 cells transiently
transfected with PITX2A expression clone. b-c Q-PCR assay of TGF-B1/B2/B3 (for OAW-42 cells; b) and TGF-B2/B3 (for SKOV-3 cells; c) was done with
specific primers with RNA isolated from PITX2-overexpressed respective cells. The comparative expression of respective genes is shown as relative
‘fold’ change (mean ± S.E.M). * represents p < 0.05. d-e The conditioned-medium (PITX2-CM) was collected after transient transfection with PITX2A.
Freshly plated serum-starved SKOV-3 (d) and OAW-42 (e) cells were incubated for 2 h with PITX2-CM alone or in combination with 20 ng/ml
TGFRI (RI) followed by Western blot of the lysates with p-SMAD2 and SMAD2 antibodies. The lysate of the cellstreated with rhTGF-β1 (rh; for
30 min) was blotted with the respective antibodies. Here, GAPDH was used as loading control. f Confocal imaging for p-SMAD2 was performed
in SKOV-3 cells treated or transfected as mentioned, where the left panel shows the p-SMAD2 expression, DAPI-stained nuclei in the middle panel
and the right panel shows their merged image. The images were taken at the same exposure time. Scale bar, 20 μm. g Lysates were prepared
from PITX2A-siRNA trasfected OAW-42 cells for Western blot with PITX2-antibody. Here, α-tubulin was used as loading control. h OAW-42 cells
were transfected with p3TP-Lux vector alone or along with expression constructs of PITX2 isoforms or pcDNA3 (empty vector) and treated with
TGFRI for 16 h for luciferase assay. The activities are shown as mean fold enhancement compared to the p3TP-construct without PITX2 expression
after normalization with renilla luciferase activity
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PITX2A; the invasiveness was sharply reduced upon
TGFRI treatment. In parallel, treatment of PITX2A-
transfected cells with the rhTGF-β1 increased the invasion
by ~3.5 folds (p < 0.01; Fig. 4c and e). The above-
mentioned effects were observed on OAW-42 cells (Fig. 4d
and f) as well.
Further, the involvement of TGF-β signalling pathway
on PITX2-mediated invasion and migration was verified
by monitoring the expression of relevant genes . The ex-
pression of the SNAI1 was increased ~ 7 folds (p < 0.05) in
PITX2A-overexpressed SKOV-3 cells, which was reduced
to < 2 folds (p < 0.01; Fig. 4g) by TGFRI. The rhTGFβ-1
alone induced the mRNA of SNAI1 by ~ 4 folds (p < 0.01;
Fig. 4g). In contrast, PITX2A-suppressed expression of
CDH1 was rescued by TGFRI-treatment by > 60 %
(p < 0.05; Fig. 4h). Similarly, the MMP9 expression was
shown to be induced by ~ 16 folds (p < 0.01; Fig. 4i) by
PITX2A-transfection. However, the TGFRI severely
reduced it to ~ 8 folds (p < 0.05; Fig. 4i). In agreement to Q-
PCR result, the Western-blot with specific antibodies
supported the regulation at the protein level by TGF-β sig-
nalling pathway as well (Fig. 4j). To determine whether
Snail and MMP9 contribute to PITX2-stimulated invasion,
SKOV-3 cells were transfected with their respective siRNAs
alone or along with PITX2A-expression vector followed by
matrigel invasion assay. PITX2A induced the invasion of
cells by > 2.5 folds (Fig. 3c), which was reduced by ~ 60 %
(p < 0.01; Fig. 4k) by either SNAI1-or MMP9-siRNA trans-
fection into PITX2A-overexpressed cells.
PITX2-mediated up-regulation of Activin-A leads to
increased p-SMAD2 levels
As p-SMAD2 level was higher in PITX2-CM treated
cells than that of rhTGF-β1 (Fig. 2c), we checked for
other PITX2-regulated ligands for possible explanation.
Since several PITX2-specific cis-elements are present in
the promoter of INHBA (Fig. 5a), we verified PITX2-
mediated trans-activation of the same. ChIP assay with
PITX2 antibody followed by PCR showed amplifications
of the INHBA (Fig. 5b) promoter, indicating the binding
of PITX2 with the respective promoter. The primers of
an unrelated gene (GAPDH promoter) did not show any
PCR amplification from the PITX2-IP DNA (Fig. 5c). All
PCR products were sequenced to confirm their iden-
tities. Next, the promoter region of INHBA (Fig. 5a) was
cloned into pGL3-basic vector. Transfection of OAW-42
cells with this reporter clone along with PITX2 ex-
pression constructs revealed activation of the promoter
by ~20-25 folds (Fig. 5b) compared to transfection with
the reporter construct alone. Q-PCR demonstrated sig-
nificant up-regulation of the mRNA level of INHBA
(Fig. 5e) upon ectopic over-expression of PITX2 iso-
forms. To find out the physiological effect of Activin-A,
the homodimer form of INHBA, serum-starved OAW-
42 cells were treated with recombinant protein.
Westerm immunoblotting confirmed the induction of p-
SMAD2 level in the cell lysates (Fig. 5f ), indicating
activation of TGF-β signalling pathway. Induction of p-
SMAD2 was higher in cell lysates treated with 100 ng/ml of
rhActivin-A compared to that treated with 10 ng/ml con-
centration. Therefore, the following experiments were done
with 100 ng/ml rhActivin. Activin-A appeared to contribute
directly to PITX2-induced p-SMAD2 level, as use of neu-
tralizing antibody to Activin-A reduced the PITX2-CM-
enhanced p-SMAD2 (Fig. 5g).
Activin-A induces EMT and invasion in both normal and
ovarian cancer cells
The trans-activation of INHBA gene by PITX2 (Fig. 5)
made us curious whether it affects cellular invasiveness.
Next, the treatment of IOSE and OAW-42 cells with
rhActivin-A, the homodimer form of INHBA, resulted
in the morphological changes (as checked by bright field
microscopy; Fig. 6a i-ii) and actin rearrangements
(through phalloidin staining followed by confocal mi-
croscopy; Fig. 6b i-ii) resembling that of mesenchymal
cell type. For detailed study, we assessed the effect of
activin-A on the expression of genes associated with
cellular invasion and EMT. The expression of the EMT
markers, including CDH1, CLDN7 was decreased by ~
60-70 % (Fig. 6c; p < 0.05) whereas the levels CDH2
and VIM were increased by ~2 and 2.5 folds respect-
ively (Fig. 6d) in IOSE cells. In addition, the expression
of transcription factors including SNAI1, SNAI2, ZEB1,
ZEB2 was increased by ~ 2-3 folds (Fig. 6e, p < 0.01),
while MMP9 expression was found ~ 5 folds increase
(Fig. 6f) by treatment of OAW-42 cells with rhActivin-A.
In addition, reduction in CLDN1 and CLDN7 and increase
in VIM was observed by activin-A treatment (Fig. 6g). The
change in the protein levels of VIM and E-cadherin by
rhActivin-A (Fig. 6h) was consistent with Q-PCR data of
the same in IOSE. Thus, overall findings clearly indicate
the involvement of activin in promoting EMT.
Activin-A contributes to PITX2-induced cellular invasion
We next attempted to investigate the possible contribution
of activin-A in PITX2-induced invasion and EMT in ovar-
ian cancer cells. rhActivin-A treatment resulted in ~4 fold
increase in invasion of OAW-42 cells compared to controls
as shown by matrigel invasion assay (Fig. 7a-b). In contrast,
PITX2A-enhanced cell invasiveness was reduced by ~ 50 %
on transfection with INHBA-siRNA (Fig. 7a-b). PITX2A in-
creased mRNA levels of MMP9 (Fig. 7c), SNAI1 and ZEB1
(Fig. 7d) that were significantly reduced by transfection with
activin-A siRNA. Similarly, the mRNA levels of the mesen-
chymal marker VIM was up-regulated by ~ 2.5 folds on
PITX2A over-expression, whereas it decreased drastically
upon activin-A knockdown in presence of PITX2A over-
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expression (Fig. 7e). Knockdown of INHBA rescued the
PITX2A-mediated suppression of the epithelial marker
CLDN7 (Fig. 7f).
Discussion
High mortality rates of ovarian cancer patients are not
only due to the rapid resistance acquired by the tumor
cells to conventional therapies but also due to their
overtly aggressive and invasive behaviour [29]. Metastatic
cells undergo various genetic and epigenetic changes that
increase motility and invasive behavior [29]. Evidence sup-
ports a strong positive role of both TGF-β ligands and their
receptors in promoting carcinogenesis through invasive
transformation. In tumor cells, increased secretion of the
TGF-β ligands enhance metastasis and promotes tumori-
genesis [30, 31]. The three mammalian isoforms, TGF-β1/
β2/β3, are encoded by different genes which function
throughtrans-membrane receptors with intrinsic cytoplas-
mic serine-threonine kinase domains [32]. Among those,
TGF-β1 is most frequently up-regulated in tumor cells [33]
and is the focus of most studies, including ours.
TGF-β/SMAD signalling pathway has been earlier dem-
onstrated to be operational in ovarian cancer cells [34] and
our present report demonstrated its activation in human
ovarian tumors (Fig. 1). We showed up-regulation of a
homeodomain transcription factor, PITX2, in similar tissue
sections [28], indicating its possible involvement in ovarian
cancer. Recently the association of PITX2 with cancers of
thyroid, prostate, colon and breast [26, 27, 35] has been
highlighted. In addition, inactivation of PITX2 leads to
apoptosis of pituitary gonadotrophs [36] suggesting an ac-
tive association between PITX2 and cancer, although no
such report is available in the context of ovarian cancer.
Considering the importance of the regulation of TGF-β
pathway by homeodomain proteins including HOXB9 in
promoting tumorigenesis [37], we investigated the possible
association of PITX2 and TGF-β signalling in ovarian can-
cer. Our experiments demonstrated that PITX2 isoforms
differentially enhanced the expression of TGFB1/2/3 genes.
In addition, PITX2-activated TGF-β signalling pathway
(Fig. 1) was evidenced by p-SMAD2 induction as well as its
nuclear localization by PITX2-CM in ovarian cancer cells.
We further investigated the role of PITX2-activated
TGF-β pathway in EMT and invasion, the key steps in
ovarian cancer progression [38]. We showed a significant
regulatory role of PITX2 in inducing EMT through expres-
sion of EMT markers (Fig. 2) and phenotypic changes in
PITX2-overexpressed cells. Earlier studies demonstrated
the regulatory function of HoxB7 and HoxA10, the homeo-
domain transcription factors, in controlling EMT [21, 39].
Here we show an important role of PITX2 in promoting
EMT. In addition, Snail and Slug are important effectors
for invasiveness. They act through transcriptional repres-
sion of E-cadherin, thereby [40] facilitating metastasis [41]
through basement membrane degradation, associated with
lower overall survival in ovarian cancer [42]. Moreover, ec-
topic expression of Snail or Slug results in enhanced inva-
siveness and tumorigenicity in the SKOV-3 cells [43]. We
showed up-regulation of Snail/Slug and downregulation of
E-cadherin upon over-expression of PITX2 isoforms (Fig. 2).
The activity of MMPs has been implicated in tumor growth
and metastasis through ECM remodelling [44] and can be
considered as an independent prognostic marker [45]. We
found up-regulation of MMP9 by PITX2 in ovarian cancer
cells, suggesting PITX2 as a key regulator of relevant genes
that control invasion/metastasis of ovarian cancer cells.
Our data suggests that either recombinant TGF-β1 or
PITX2 over-expression can induce motility/invasion in
ovarian cancer cells (Fig. 4). When PITX2-transfected
cells were treated with rhTGF-β1, a synergistic activity
on cellular invasion was observed. Quite surprisingly,
PITX2-transfected cell lysates showed higher level of
p-SMAD2 compared to rhTGF-β1-treated ones (Fig. 1c-d).
We postulated involvement of some other factors up-
regulated by PITX2-overexpression that could increase
p-SMAD2. Indeed, we found activin-A as one such factor
that is enhanced by PITX2. In addition, PITX2 binds to the
bicoid-like elements present in the promoter of INHBA
gene and trans-activates it, enhancing the formation of
activin-A (Fig. 3). In ovary, activin is predominantly
expressed in the granulosa cell layer of follicles and plays
important roles in several physiological processes, including
folliculogenesis, steroid hormone production, and oocyte
maturation by acting either as a paracrine or autocrine fac-
tor [46]. Through the activation of activin signaling medi-
ated by ActRIB-Smad2 system, activin-A facilitates the
expression of FSH receptor and aromatase activity which is
essential for ovarian granulosa cell function, differentiation
(See figure on previous page.)
Fig. 3 Over-expression of PITX2 affects markers for EMT and invasion in ovarian cancer cells. a-d The expression level of SNAI1, SNAI2, MMP9,
CLD4, CLD7, DSM and VIM genes were quantified by Q-PCR assay after ectopic over-expression of PITXA/B/C into SKOV-3 (a and c) and OAW-42
(b and d) cells. The expression of CDH1 was assessed in SKOV-3 cells (Fig A-ii) upon transient transfection of PITX2 isoforms. The comparative
expression of respective genes is shown as relative ‘fold’ change (mean ± S.E.M). e-f Western blot analysis of the proteins with respective
antibodies was performed with the lysates of PITX2-tranfected SKOV-3 (e) and OAW-42 (f) cells. Here, GAPDH was used as internal loading
control. g Bright field microscopy images exhibit the epithelial phenotype of the control and mesenchymal phenotype of PITX2A-transfected IOSE (G-i)
and SKOV3 (G-ii) cells cells. h Phalloidin staining of IOSE cells (i) and imunofluorescence imaging of E-cadherin was performed for the SKOV-3 cells (ii).
i-j Q-PCR assay was performed to check the expression of CLDN1, CLDN7, CDH2 and VIM in PITX2-overexpressed IOSE cells. *represents p< 0.05
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and folliculogenesis [47, 48]. Both experimental and clinical
studies suggest the elevated level of activin-A in the serum
of granulosa cell tumor patients [49]. Our finding could
add another dimention to the function and regulation of
activin-A, particularly, in epithelial ovarian cancer.
We showed earlier that PITX2 interacts with and regu-
lates, FGF16, a prime inducer of invasion of ovarian cancer
cells [28]. We also showed significant involvement of
PITX2 in regulating the Wnt signalling pathway that in-
duces proliferation of ovarian cancer cells [50], creating an
auto-regulatory feedback loop. The present study is the first
comprehensive investigation on the regulatory role of
PITX2 on invasive behavior in ovarian carcinoma cells.
TGF-β pathway is considered to be a prime regulator in in-
ducing invasion of ovarian cancer cells. Here, we identified
a novel regulatory role of PITX2 through expression of
both TGFB and INHBA genes. The involvement of activin-
A, the homodimer form of INHBA, in inducing invasion
leading to epithelial ovarian cancer progression (apart from
GCT) has been demonstrated for the first time in this
study. Thus, it is imperative to say that PITX2 appears to
act as an important regulatory protein that controls initi-
ation and progression of epithlial ovarian cancer. Further
study may explore the possible involvement of PITX2 in
GCT. TGF-β has been shown to synergize with oncogenic
pathways. Evidence suggests that Wnts can also cooperate
with other signaling pathways during tumorigenesis. PITX2
lies upstream of these two pathways, thus playing a signifi-
cant role in tumorigenesis and metastasis.
Conclusion
The major findings of our study are: a) PITX2 up-regulates
the expression of ligand genes of TGF-β superfamily,TGFB
and INHBA followed by induction of SMAD2/3-dependent
TGF-β signalling pathway; b) through the activation of
TGF-β pathway, PITX2 regulates the expression of genes
that enhances invasion and EMT of ovarian cancer cells; c)
This is the first report to show the direct involvement of
activin-A, the homodimer form of INHBA, in promoting
invasion and EMT of both non-cancerous and cancerous
cells. (d) Overall this present report is first of its kind to
show the direct involvement of a homeodomain transcrip-
tion factor, PITX2, in the progression of ovarian cancer.
Methods
Cell culture, treatment of growth factor and inhibitors
Human ovarian adenocarcinoma cells, SKOV-3 (ATCC,
USA) and OAW-42 (Sigma-Aldrich; USA) were main-
tained in McCoy’s 5A (Sigma) and DMEM (Invitrogen)
respectively; both supplemented with 10 % fetal bovine
serum (FBS, Invitrogen, USA), 100 U/ml penicillin and
100 μg/ml streptomycin both Invitrogen; [51]. Human
immortalized ovarian surface epithelial cells, IOSE (a kind
gift from Drs. N. Aueresperg and Clara Salamanca,
Vancouver, Canada) was maintained in Medium199
(Invitrogen) and MCDB105 (Sigma-Aldrich; USA) in
1:1 ratio supplemented with 10 % FBS, 100 U/ml penicillin
and 100 μg/ml streptomycin. Here, the low-passage
cultures of human ovarian surface epithelium cells
(isolated by scraping from human ovarian surface tis-
sue) were immortalized by transfecting with SV40
large-T antigen viral particles [52].
Human recombinant TGF-β1 (rhTGF-β1; Calbiochem,
Germany) was used at 10 ng/ml for 30 min and 8 h for
Western-blot and Q-PCR assay respectively. TGF-β
receptorI kinase inhibitor (TGFRI; 20 ng/ml) was pro-
cured from Calbiochem (cat. no. 616451). Recombinant
human Activin-A (rhActivin-A; ACRO Biosystems) was
used at 100 ng/ml for 30 min and 24 h for Western-blot
and Q-PCR assay respectively. Activin-A neutralizing
antibody (Novus Biologicals) was used at a concentration
of 2 μg/ml. Prior to each treatment, the cells were
serum-starved for 16 h and the control cells were treated
with vehicles (0.1 % BSA in 1X PBS or DMSO).
Expression and reporter constructs
The 1.7 kb upstream promoter region of INHBA gene
was amplified by PCR using human genomic DNA as
template and then cloned into pGL3 basic vector (Pro-
mega) at MluI/HindIII site. The primer sequences used
(See figure on previous page.)
Fig. 4 The regulation of invasion and migration is served by PITX2-mediated activation of TGF-β signalling pathway. Wound healing assay was
performed of SKOV-3 (a) and OAW-42 (b) cells after treatment with rhTGFβ1 (ii), transient transfection of PITX2A (iii) and treatment with rhTGFβ1
(iv) or TGFRI (v) of PITX2-transfected cells in the time course of 24 h. T = 0 h at control cells (i) signifies the time of scratching the cells with pipette
tips. The arrows indicate the width of wound and the assay was repeated three times independently. Scale bar: 50 μm. Transwell migration and invasion
assay was performed in SKOV-3 (c) and OAW-42 (d) cells after treatment and/or transient transfection as mentioned. Scale bar: 200 μm. Cells at three
independent fields for each well were counted and plotted with error bar for SKOV-3 (e) and OAW-42 (f) cells. g-i pcDNA3 or PITX2A-transfected
SKOV-3 cells were treated with rhTGFβ1 (10 ng/ml) or TGFRI (20 ng/ml) followed by isolation of RNA and Q-PCR with the primers of SNAI1 (g), CDH1
(h) and MMP9 (i). Relative gene expression is indicated as ‘fold’ change in the Y-axis (mean ± SEM). * represents p< 0.01. j Lysates of the cells transiently
transfected and/or treated as indicated were immunoblotted with respective antibodies and the representative gel image was shown. k Transwell invasion
assay was performed with SKOV-3 cells after transient transfection as mentioned (top). Cells at three independent fields for each well were counted and
were plotted with error bar (bottom). The efficiency in knocking down the expression of SNAIL and MMP9 proteins by SNAI-(SN)-si and MMP9-si
respectively was verified by Western blot of the transfected cell lysates with respective antibodies. Here, GAPDH was used as loading
control (bottom)
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to clone the promoters are mentioned in Table 1,
where the restriction enzyme sites are underlined. All
constructs were sequenced by ABI Prism Automated
DNA Sequencer (Perkin Elmer, USA). Sequence align-
ment and data analysis were performed through
BLAST search (NCBI Gen Bank). The TGF-β inducible
p3TP-Lux luciferase reporter vector was procured
from Addgene, USA. pRL-CMV (Promega, USA) vec-
tor with Renilla-luciferase gene was used to normalise
the luciferase activity. Expression plasmids of three
isoforms of PITX2 (PITX2A/B/C) were described earl-
ier [28]. To evaluate the expression profile of the TGFB
genes as well as the genes associated with invasion and
EMT, we performed over-expression of three isoforms
of PITX2 (PITX2A/B/C). As a similar trend was observed
in the change in gene expression by these isoforms, we used
PITX2A isoform as representative in the subsequent
physiological experiments like activation of TGF-β pathway,
Fig. 5 PITX2-regulated INHBA activates SMAD2 level. a Schematic diagram shows the 2 kb upstream region of INHBA promoter with the
PITX2-specific bicoid-like (as +) elements. Here, the location of primers used to clone 1.7 kb region in pGL3 vector has been depicted with
black solid arrow, while that used for ChIP-PCR has been shown with hollow arrows. b-c ChIP with SKOV-3 cells followed by the PCR showed
the amplification of the INHBA promoter (b) from the chromatin input and from PITX2-IP DNA as indicated in the lanes. The PITX2 antibody
used in this assay recognizes all three isoforms of PITX2. Amplification of respective promoters was not observed by PCR performed with
IgG-IP and no antibody control sets. c Primers of an unrelated gene did not show amplification from PITX2-IP DNA. (d) The INHBA promoter
as shown in Fig A was cloned into pGL3-basic vector. OAW-42 cells were transiently co-transfected with the construct alone or in combination with
PITX2 isoforms followed by luciferase assay. The reporter activity of each clone was calculated in terms of fold change in PITX2-overexpressed
cells compared with empty vector-transfected cells, after normalization with renilla luciferase activity. e Q-PCR analysis of the INHBA gene
with specific primers was performed with the RNA isolated from PITX2A/B/C-transfected OAW-42 cells. Relative gene expression is indicated
as ‘fold’ change in the Y-axis (mean ± SEM). The statistical analysis is done as described previously.* represents p < 0.05. f Western blot was
performed to check the level of p-SMAD2 in OAW-42 cells after treatment with rhActivin-A (rhA10: 10 ng/ml and rhA100: 100 ng/ml) for 30
mins. g The levels of p-SMAD2 was assessed on treating the cells with PITX2A-conditioned medium (PITX2-CM), rhActivin-A (rhA: 100 ng/ml)
or PITX2-CM in presence of activin neutralizing antibody (Pitx2-CM + Ab)
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matrigel invasion, wound healing and cell proliferation
assay etc.
Transient transfection and luciferase assay
For reporter assay, 5 × 104 cells were seeded on 12-well
culture plates. After 24 h, p3TP-Lux vector (0.4 μg) was
transiently transfected alone or along with PITX2 ex-
pression vectors (0.4 μg) with Lipofectamine 2000 (Invi-
trogen). After 4 h of transfection, the medium was
replaced with fresh incomplete one supplemented with
either TGFRI or DMSO for next 16 h. Each transfection
was normalized with pRL-CMV vector (0.04 μg). In the
following day, cells were harvested and firefly/renilla
luciferase activity was determined [50]. The transfection
of pGL3-reporter vectors and the subsequent assay
was performed following the same protocol. Each
transfection was performed in triplicate and the experi-
ments were repeated thrice.
To over-express PITX2 isoforms, 1 μg of expression
constructs were transfected per 105 cells/well in 6-well
plate using Lipofectamine 2000 (Invitrogen). After 24 h
and 48 h of transfection, the cells were harvested to iso-
late RNA and protein respectively. For the treatment of
rhTGF-β1/TGFRI, the medium was replaced after 4 h of
PITX2 transfection with fresh one supplemented with
these factors. The cells were harvested after 16 h for
RNA/protein isolation. To collect conditioned medium
(CM), PITX2A was transiently transfected as men-
tioned earlier. After 6 h, the medium was replaced with
fresh serum-free one, which was collected after 24 h of
transfection and added directly or in combination with
rhTGF-β1/TGFR1 to the freshly plated cells. The
treated cells were harvested after 2 h for protein
Fig. 6 Activin-A promotes EMT in ovarian non-cancerous and cancer cells. a-b IOSE and OAW-42 cells were treated with rhActivin-A and
their morphological changes were observed through bright field (A i-ii) as well as through confocal microscopy after phalloidin staining
(B i-ii). c-d RNA was isolated from the IOSE cells to check the expression of CDH1, CLDN7 (c) and CDH2, VIM (d) by Q-PCR. e-g RNA isolation
was done from the OAW-42 cells to quantify ZEB1, ZEB2,SNAI1, SNAI2 (e), MMP9 (f), CLDN1,CLDN7 and VIM (g) by Q-PCR with specific primers.
Relative gene expression is indicated as ‘fold’ change in the Y-axis (mean ± SEM). The statistical analysis is done as described previously.
*represents p < 0.05. h Western Blot was done with lysates of IOSE cells with respective antibodies as mentioned. GAPDH was used as the
loading control
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isolation. The control cells were transfected with
empty vector (pcDNA3.1 Myc-His) in each case.
siRNA and transfection
The siRNAs against SNAI1, MMP9 and INHBA (all from
Santa Cruz Biotechnology, USA) were used at 20 nM/well
using 2 μl Lipofectamine RNAiMAX (Invitrogen) in the
cells seeded in 6-well plates. The RNA interference against
PITX2 was carried out by the ON-TARGET plus SMART
pool siRNA at 20 nM/well using 2 μl of Dharmafect-1
transfection reagent (Dharmacon) in cells seeded in 6-well
culture plates. After 48 h of transfection, the cells were har-
vested for RNA/protein isolation. When required, rhTGF-
β1 was added after 24 h of respective siRNA transfection
into the cells.
Quantitative Real-time RT-PCR (Q-PCR)
Total RNA was isolated from ovarian cell lines using TRI-
reagent (Sigma) following the standard protocol [53].
First-strand cDNA synthesis followed by Q-PCR assay
was performed as described [28]. The comparative CT
method (ΔΔCT) was used to measure relative gene expres-
sion where the fold enrichment was calculated as: 2
− [ΔCT (sample) −ΔCT (calibrator)]. Here, ΔCT is the CT of tar-
get gene subtracted from the CT of the housekeeping gene
[50]. The primer sequences are mentioned in Table 2.
Table 1 The sequence of the oligonucleotide primers used to amplify specific regions of the promoter
Gene Name
& Acc no
Region amplified Forward primer (5′- 3′) Reverse primer (5′- 3′) Amplicon size (kb) Tm (°C)
INHBA;
NC_000007.14
41702063 - 41700378 GGACGCGTGAACGCTTTAACAGATGGAC GGAAGCTTGCAAAAGTTGTTGTGATTGC 1.7 54
Fig. 7 PITX2 acts through Activin-A to affect the cellular invasion and EMT. a Matrigel transwell assay was performed in OAW-42 cells which
were treated either with rhActivin-A or transfected with INHBA-siRNA in presence or absence of PITX2A-overexpression and the percentage
of cell invasion was calculated. Scale bar 100 μm. b Cells at three independent fields for each well were counted and plotted with error bar.
c-f RNA was isolated from cells tarnsfected with INHBA-siRNA in presence or absence of PITX2A- overexpression and the expression of
MMP9, ZEB1, SNAI1, VIM, CLDN7 was quantified by Q- PCR with specific primers. Relative gene expression is indicated as ‘fold’ change in the
Y-axis (mean ± SEM). The statistical analysis is done as described previously.*represents p < 0.05
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Chromatin-immunoprecipitation (ChIP)
ChIP with SKOV-3 cells was performed following the
methods described earlier [50]. For ChIP-PCR, the
immunoprecipitated (IP) and input DNA were used at
equal quantity following the conditions: 95 °C for 30 s,
annealing at specific temp for 30 s and extension at
72 °C for 30 s, for 30 cycles. The information of the
primers is shown in Table 3.
Western blot analysis
Cell lysis and protein extraction was performed as de-
scribed previously [51] and subjected to immunoblotting
with antibodies specific for the proteins including, PITX2
(Chemicon, 1:1000), α-SMA (Sigma; 1:1000 dilution),
claudin-7, MMP9 (both Santa Cruz; 1:1000 dilution),
GAPDH (1:3000), E-cadherin, SNAIL, vimentin, p-SMAD2
and SMAD2 (all 1:2000 dilution; all from Cell signalling
technology, USA).
Confocal microscopy
Immunofluorescence staining with anti-p SMAD2 (1:100)
E-cadherin (1:100) and PITX2 (1:100) antibodies followed
by Alexa-fluor 488-conjugated secondary antibody was
performed as described previously [28]. For phalloidin
staining 105 cells/well were plated in 6-well plate. After
24 h of PITX2A transfection or rhActivin-A treatment,
actin filament bundle formation was observed by phalloidin
staining as mentioned previously [54] followed by imaging
with confocal microscopy.
Wound healing assay
Serum-starved cells at 70 % confluency were transfected
with PITX2A-construct. After 4 h, medium was replaced
by fresh and incomplete one supplemented with rhTGF-
β1/TGFRI. In additional experiment, treatment was also
given in other set of serum-starved cells to check the ef-
fect of only TGF-β1/TGFRI on migration. Scratching
was carried out with a 200 μl pipette tip prior to the
treatment and mentioned as t = 0 h at the figure. Cells
were washed several times with PBS to remove the de-
tached ones and supplied with new growth medium.
Photographs of the scratches were taken at 0 and 24 h
using an inverted microscope (Leica) equipped with a
Scion digital camera and in-built software (Leica appli-
cation suite v3.0).
Table 2 The sequence, respective amplicon size and Tm of the oligonucleotide primers used in Q-PCR
Gene Name Forward primer (5′- 3′) Reverse primer (5′- 3′) Amplicon size (bp) Tm (°C)
18S rRNA GATTCCGTGGGTGGTGGTGC AAGAAGTTGGGGGACGCCGA 134 60
POLR2A TGGACCCACCGGCATGTTCT GCCCCTGGGGTCATTCCACT 141 60
CLDN4 GGCTGCTTTGCTGCAACT CAGAGCGGGCAGCAGAATAC 110 60
CLDN7 GTGGCAGATGAGCTCCTATGC CATCCACAGCCCCTTGTACA 80 60
DSM GCAGCAAAGGGCGGAGAT TGTTAATGTGCTGCTCCACTGA 80 60
VIM ACACCCTGCAATCTTTCAGACA GATTCCACTTTGCGTTCAAGGT 80 60
FN1 CCTTCATGGCAGCGGTTT AGCGTCCTAAAGACTCCATGATCT 94 60
PITX2 CGCGAAGAAATCGCTGTGT CGACGATTCTTGAACCAAACC 78 58
TGFB1 GTGACAGCAGGGATAACACACTG CATGAATGGTGGCCAGGTC 80 60
TGFB2 GCTGAGCGCTTTTCTGATCCT CGAGTGTGCTGCAGGTAGACA 80 60
TFGB3 CACCACAACCCTCATCTAATCCT CCTGGCCCGGGTTGTC 100 60
SNAI1 TCGGAAGCCTAACTACAGCGA AGATGAGCATTGGCAGCGAG 140 60
SNAI2 ATGAGGAATCTGGCTGCTGT CAGGAGAAAATGCCTTTGGA 119 60
CDH1 GTCACTGACACCAACGATAATCT TTTCAGTGTGGTGATTACGACGTA 100 60
MMP9 ACCTCGAACTTTGACAGCGAC GAGGAATGATCTAAGCCCAGC 113 60
INHBA GTGAGTGCCCGAGCCATATAG CATGCGGTAGTGGTTGATGACT 80 60
CDH2 CCATCAAGCCTGTGGGAATC GCAGATCGGACCGGATACTG 76 60
ZEB1 CAATGATCAGCCTCAATCTGCA CCATTGGTGGTTGATCCCA 117 60
ZEB2 AAGCCCCATCAACCCATACAAG AAATTCCTGAGGAAGGCCCA 124 60
Table 3 The sequence, respective amplicon size and Tm of the oligonucleotide primers used in ChIP-PCR
Gene Name & Acc no Region amplified Forward primer (5′- 3′) Reverse primer (5′- 3′) Amplicon size (kb) Tm (°C)
INHBA; NC_000007.14 41702097- 41701831 GGCTTATGTGTGGGAAAGAA ACCAGTGCATTCATAGACAG 265 55.5
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In vitro invasion assay
Transwell membranes coated with Matrigel (BD
Biosciences, USA) were used to assay in vitro invasion as
mentioned previously [53]. In brief, 2.5 × 105 cells were
seeded in the upper chamber in serum-free medium and
FBS or rhTGF-β1/TGFRI was added in the lower chamber.
To check the effect of PITX2, MMP9 and SNAIL on TGF-
β-mediated invasion, cells were transiently transfected with
respective construct or siRNAs on previous day, allowed to
recover overnight and then serum-starved for additional
16 h. The cells were then trypsinized, counted and equal
number of transfected cells were added in the upper cham-
ber and allowed to invade in presence of TGF-β or
TGFRI.To understand the role of activin-A in PITX2-
mediated cell invasion, the cells were transiently transfected
with PITX2 expression construct or INHBA-siRNAs or
both on previous day, allowed to recover overnight and
then serum-starved for additional 16 h. The cells were then
trypsinized, counted and equal number of transfected cells
were added in the upper chamber and allowed to invade in
presence or absence of rhActivin-A. After incubating for
22 h at 37 °C in 5 % CO2, the invaded cells were fixed,
stained and counted under microscope. Three independ-
ent experiments were performed followed by statistical
analysis.
Immunohistochemistry (IHC) with immunofluorescence
(IF)-based detection
Tissue sample blocks used for IHC were archival materials
provided by the Department of Pathology, Institute of Post
Graduate Medical Education and Research and SSKM Hos-
pital, Kolkata, India. Isolated tissues were fixed, processed,
and sectioned as mentioned earlier [55]. The sections were
then blocked in 5 % BSA in 1XTBS-T for 30 min and incu-
bated for 2 h with the anti-pSMAD2 (1:100) and antibody
diluted in 1XTBS containing 0.1 % BSA. The slides were
then washed and incubated for 1 h with the secondary anti-
body (Alexa Fluor-488; 1:500) followed by staining with
DAPI. The IF-staining was performed in all collected sam-
ples and the representative images have been shown.
Statistical analysis
All data were expressed as mean ± SEM and the ± SEM are
represented by error bars. The statistical significance was
calculated by two-tailed Student’s t-test. p < 0.05 was con-
sidered as significant. The experiments were done at least 3
times in duplicate unless otherwise stated.
Additional file
Additional file 1: Figure S1. The expression of PITX2 is up-regulated
in human ovarian cancer. (A) The level of PITX2 was observed by IHC
in human ovarian tissue-sections with specific antibody followed by
Alexa Fluor-488 (green) of low malignant potential (i; n = 20) and high
malignant potential metastatic adenocarcinoma patients (ii; n = 20).
The DAPI-stained nuclei and the merged images were also shown.
Scale bar, 10 μm. (TIFF 28495 kb)
Abbreviation
DAPI: 4′, 6-Diamidino-2-phenylindole; TGF: Transforming growth factor;
MMP: Matrix metalloprotease; SMAD: Mothers against decapentaplegic,
Drosophila; EMT: Epithelial-mesenchymal transition; GAPDH: Glyceraldehyde-3
phosphate dehydrogenase; ECM: Extracellular matrix; SMA: Smooth muscle actin;
CLDN: Claudin; CDH1: E-cadherin; CDH2: N-cadherin; SNAI1: SNAIL; SNAI2: SLUG;
INHBA: activin-A; IOSE: Immortalized ovarian surface epithelium.
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